Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short term Debt: 2014-2021

Historic Short term Debt for ImmunityBio (IBRX) over the last 7 years, with Sep 2021 value amounting to $8.7 million.

  • ImmunityBio's Short term Debt rose 541.37% to $8.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $8.7 million, marking a year-over-year increase of 541.37%. This contributed to the annual value of $14.8 million for FY2020, which is 2953.09% up from last year.
  • According to the latest figures from Q3 2021, ImmunityBio's Short term Debt is $8.7 million, which was down 47.96% from $16.7 million recorded in Q2 2021.
  • In the past 5 years, ImmunityBio's Short term Debt ranged from a high of $17.8 million in Q1 2021 and a low of $486,000 during Q4 2019.
  • Its 3-year average for Short term Debt is $6.0 million, with a median of $1.5 million in 2019.
  • As far as peak fluctuations go, ImmunityBio's Short term Debt tumbled by 71.34% in 2019, and later spiked by 2,953.09% in 2020.
  • ImmunityBio's Short term Debt (Quarterly) stood at $2.4 million in 2017, then decreased by 28.23% to $1.7 million in 2018, then slumped by 71.34% to $486,000 in 2019, then spiked by 2,953.09% to $14.8 million in 2020, then skyrocketed by 541.37% to $8.7 million in 2021.
  • Its Short term Debt stands at $8.7 million for Q3 2021, versus $16.7 million for Q2 2021 and $17.8 million for Q1 2021.